<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-5173</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Medicina Geral e Familiar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Med Geral Fam]]></abbrev-journal-title>
<issn>2182-5173</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Medicina Geral e Familiar]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-51732017000100004</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Adesão à terapia antirretroviral em pacientes infetados pelo VIH nos cuidados de saúde primários em Nampula, Moçambique]]></article-title>
<article-title xml:lang="en"><![CDATA[Adherence to antiretroviral treatment among HIV positive patients in primary health care in Nampula, Mozambique]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pires]]></surname>
<given-names><![CDATA[Paulo das Neves]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marega]]></surname>
<given-names><![CDATA[Abdoulaye]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Creagh]]></surname>
<given-names><![CDATA[José Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade Lurio  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Moçambique</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade Lurio Faculdade de Ciências de Saúde ]]></institution>
<addr-line><![CDATA[Nampula ]]></addr-line>
<country>Moçambique</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<volume>33</volume>
<numero>1</numero>
<fpage>30</fpage>
<lpage>40</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-51732017000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-51732017000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-51732017000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objetivos: Avaliar a taxa de adesão à terapia antirretroviral na província de Nampula e os fatores associados ao abandono do tratamento. Tipo de estudo: Descritivo transversal misto. Local: Centros de saúde de cinco distritos da província de Nampula, Moçambique, 2014. População: Pacientes infetados pelo vírus da imunodeficiência humana em terapia antirretroviral e pacientes que abandonaram, profissionais dos cuidados de saúde primários. Métodos: Inquérito a pacientes em terapia antirretroviral e a pacientes que abandonaram a terapia, consulta documental de processos clínicos, registos da farmácia e relatórios estatísticos do programa Vírus da Imunodeficiência Humana Adquirida, entrevista aos profissionais de saúde. Resultados: A taxa de abandono da terapia atinge os 40%. Foram inquiridos 208 pacientes em tratamento e 86 abandonos, 70% do sexo feminino, entre os 18 e os 62 anos de idade. Como causa principal de abandono 36% referem discriminação, mas 58% não dispõem de alimentos suficientes e 37% apresentam depressão. A boa adesão à terapia antirretroviral (>95% das tomas de antirretrovirais) nos últimos três meses foi estimada em 69% dos pacientes, mas 36% apresentam um mau resultado de contagem de Linfócitos T CD4 e 63% não cumprem o protocolo recomendado pelo Ministério da Saúde. Conclusões: O principal motivo alegado para o abandono da terapia antirretroviral é o estigma ligado à infeção pelo vírus da imunodeficiência humana adquirida, mas a insegurança alimentar constitui igualmente um fator determinante. Nos pacientes em terapia, a adesão estimada de 69% explica a alta incidência de infeções oportunistas (27%). O abandono da terapia em Nampula é um problema grave e complexo, resultante de fatores individuais, sociais e do funcionamento dos cuidados de saúde primários. Será necessário desenvolver uma ação interdisciplinar junto de pacientes, famílias e profissionais de saúde para inverter a situação e melhorar a adesão terapêutica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Objectives: To evaluate adherence to antiretroviral treatment in Nampula province and to identify the determinants of non-compliance. Study type: Observational study with quantitative and qualitative methods. Place: Five health centers in the Nampula province of Mozambique in 2014. Population: Patients infected with human immunodeficiency virus receiving antiretroviral treatment, patients who had abandoned treatment, and primary health care professionals. Methods: Patients on treatment and patients who were non-compliant with therapy completed a questionnaire, patient records (clinical files, pharmacy records, and statistical records) were reviewed, and interviews were conducted with health care professionals. Results: Abandonment of antiretroviral treatment reached 40%. We surveyed 208 patients on treatment and 86 patients who were non-compliant with therapy. Of these 70% were female and they were between 18 and 62 years of age. The main reason for non-compliance with treatment (36%) was stigma attached to having the infection. In addition 58% of patients do not have enough food and 37% suffer from depressive ideation. Good treatment adherence (>95% of pills were taken in the last three months) was found in 69% of patients, but 36 % of people who are adherent have a low CD4 count and 63% are not following the recommended treatment protocol. Conclusions: Perception of stigma from infection with the human immunodeficiency virus is considered the main reason for non-adherence with antiretroviral treatment, but food insecurity is also an important determinant. A treatment adherence rate of 69% explains the high incidence of opportunistic infections (27%). Abandonment of antiretroviral treatment in Nampula is a serious and complex problem due to individual, social and primary health care services factors. It will be necessary to develop an interdisciplinary intervention with patients, families, and health professionals, to reverse this situation and improve treatment adherence.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Adesão]]></kwd>
<kwd lng="pt"><![CDATA[Antirretroviral]]></kwd>
<kwd lng="pt"><![CDATA[VIH/SIDA]]></kwd>
<kwd lng="pt"><![CDATA[Cuidados de saúde primários]]></kwd>
<kwd lng="pt"><![CDATA[Moçambique]]></kwd>
<kwd lng="en"><![CDATA[Adherence]]></kwd>
<kwd lng="en"><![CDATA[Antiretroviral]]></kwd>
<kwd lng="en"><![CDATA[HIV/AIDS]]></kwd>
<kwd lng="en"><![CDATA[Primary health care]]></kwd>
<kwd lng="en"><![CDATA[Mozambique]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2"><b>ESTUDOS ORIGINAIS</b></font></p>     <p><font size="4"><b>Ades&#227;o &#224; terapia antirretroviral em   pacientes infetados pelo VIH nos cuidados de sa&#250;de prim&#225;rios em Nampula,   Mo&#231;ambique</b></font></p>     <p><font size="3"><b>Adherence   to antiretroviral treatment among HIV positive patients in primary health care in Nampula, Mozambique</b></font></p>     <p><b>Paulo das Neves Pires,<sup>1</sup> Abdoulaye Marega,<sup>2</sup> Jos&#233; Miguel Creagh<sup>3</sup></b></p>     <p>1.   Universidade Lurio, Mo&#231;ambique</p>     <p>2. M&#233;dico   Generalista, Docente, Faculdade de Ci&#234;ncias de Sa&#250;de, Universidade L&#250;rio,   Nampula, Mo&#231;ambique</p>     <p>3. Docente,   Faculdade de Ci&#234;ncias de Sa&#250;de, Universidade L&#250;rio, Nampula, Mo&#231;ambique</p>     <p><a href="#c0">Endere&ccedil;o para correspond&ecirc;ncia</a> | <a href="#c0">Direcci&oacute;n para correspondencia</a> | <a href="#c0">Correspondence</a><a name="topc0"></a></p> <hr/>     <p>&nbsp;</p>     <p><b>RESUMO</b></p>     ]]></body>
<body><![CDATA[<p><b>Objetivos:</b> Avaliar a taxa de ades&#227;o &#224;   terapia antirretroviral na prov&#237;ncia de Nampula e os fatores associados ao   abandono do tratamento.</p>     <p><b>Tipo de estudo:</b> Descritivo transversal   misto.</p>     <p><b>Local:</b> Centros de sa&#250;de de cinco   distritos da prov&#237;ncia de Nampula, Mo&#231;ambique, 2014.</p>     <p><b>Popula&#231;&#227;o:</b> Pacientes infetados pelo   v&#237;rus da imunodefici&#234;ncia humana em terapia antirretroviral e pacientes que   abandonaram, profissionais dos cuidados de sa&#250;de prim&#225;rios.</p>     <p><b>M&#233;todos:</b> Inqu&#233;rito a pacientes em   terapia antirretroviral e a pacientes que abandonaram a terapia, consulta   documental de processos cl&#237;nicos, registos da farm&#225;cia e relat&#243;rios   estat&#237;sticos do programa V&#237;rus da Imunodefici&#234;ncia Humana Adquirida, entrevista   aos profissionais de sa&#250;de.</p>     <p><b>Resultados:</b> A taxa de abandono da   terapia atinge os 40%. Foram inquiridos 208 pacientes em tratamento e 86   abandonos, 70% do sexo feminino, entre os 18 e os 62 anos de idade. Como causa   principal de abandono 36% referem discrimina&#231;&#227;o, mas 58% n&#227;o disp&#245;em de   alimentos suficientes e 37% apresentam depress&#227;o. A boa ades&#227;o &#224; terapia   antirretroviral (&gt;95% das tomas de antirretrovirais) nos &#250;ltimos tr&#234;s meses   foi estimada em 69% dos pacientes, mas 36% apresentam um mau resultado de   contagem de Linf&#243;citos T CD4 e 63% n&#227;o cumprem o protocolo recomendado pelo   Minist&#233;rio da Sa&#250;de.</p>     <p><b>Conclus&#245;es:</b> O principal motivo alegado   para o abandono da terapia antirretroviral &#233; o estigma ligado &#224; infe&#231;&#227;o pelo   v&#237;rus da imunodefici&#234;ncia humana adquirida, mas a inseguran&#231;a alimentar   constitui igualmente um fator determinante. Nos pacientes em terapia, a ades&#227;o   estimada de 69% explica a alta incid&#234;ncia de infe&#231;&#245;es oportunistas (27%). O   abandono da terapia em Nampula &#233; um problema grave e complexo, resultante de   fatores individuais, sociais e do funcionamento dos cuidados de sa&#250;de   prim&#225;rios. Ser&#225; necess&#225;rio desenvolver uma a&#231;&#227;o interdisciplinar junto de pacientes,   fam&#237;lias e profissionais de sa&#250;de para inverter a situa&#231;&#227;o e melhorar a ades&#227;o   terap&#234;utica.</p>     <p><b>Palavras-chave:</b> Ades&#227;o;   Antirretroviral; VIH/SIDA; Cuidados de sa&#250;de prim&#225;rios; Mo&#231;ambique</p> <hr/>     <p>&nbsp;</p>    <p><b>ABSTRACT</b></p>     ]]></body>
<body><![CDATA[<p><b>Objectives:</b> To evaluate adherence to   antiretroviral treatment in Nampula province and to identify the determinants   of non-compliance.</p>     <p><b>Study type:</b> Observational study with   quantitative and qualitative methods.</p>     <p><b>Place:</b> Five health centers in the   Nampula province of Mozambique in 2014.</p>     <p><b>Population:</b> Patients infected with   human immunodeficiency virus receiving antiretroviral treatment, patients who   had abandoned treatment, and primary health care professionals.</p>     <p><b>Methods:</b> Patients on treatment and   patients who were non-compliant with therapy completed a questionnaire, patient   records (clinical files, pharmacy records, and statistical records) were   reviewed, and interviews were conducted with health care professionals.</p>     <p><b>Results:</b> Abandonment of antiretroviral   treatment reached 40%. We surveyed 208 patients on treatment and 86 patients   who were non-compliant with therapy. Of these 70% were female and they were   between 18 and 62 years of age. The main reason for non-compliance with   treatment (36%) was stigma attached to having the infection. In addition 58% of   patients do not have enough food and 37% suffer from depressive ideation. Good   treatment adherence (&gt;95% of pills were taken in the last three months) was   found in 69% of patients, but 36 % of people who are adherent have a low CD4   count and 63% are not following the recommended treatment protocol.</p>     <p><b>Conclusions:</b> Perception of stigma from   infection with the human immunodeficiency virus is considered the main reason   for non-adherence with antiretroviral treatment, but food insecurity is also an   important determinant. A treatment adherence rate of 69% explains the high   incidence of opportunistic infections (27%). Abandonment of antiretroviral   treatment in Nampula is a serious and complex problem due to individual, social   and primary health care services factors. It will be necessary to develop an   interdisciplinary intervention with patients, families, and health   professionals, to reverse this situation and improve treatment adherence.</p>     <p><b>Keywords:</b> Adherence; Antiretroviral;   HIV/AIDS; Primary health care; Mozambique</p> <hr/>     <p>&nbsp;</p>    <p><b>Introdu&#231;&#227;o</b></p>     ]]></body>
<body><![CDATA[<p>Cerca de 34   milh&#245;es de pessoas viviam com o v&#237;rus da imunodefici&#234;ncia humana (VIH) no mundo   em 2010 e quase metade (47%, 6,6 milh&#245;es) das 14,2 milh&#245;es de pessoas eleg&#237;veis   para tratamento tinham acesso &#224; terapia antirretroviral (TARV).<sup>1</sup></p>     <p>A Declara&#231;&#227;o   Pol&#237;tica em VIH e S&#237;ndroma de Imunodefici&#234;ncia Humana Adquirida (SIDA), da   Assembleia das Na&#231;&#245;es Unidas, de 2011, constatava: &#8220;O Mecanismo Internacional   de Aquisi&#231;&#227;o de Medicamentos baseado no financiamento inovador e centrado no   acesso, qualidade e redu&#231;&#227;o de pre&#231;os dos medicamentos antirretrovirais (ARV)   permitiu a expans&#227;o do acesso &#224; TARV. O acesso a medicamentos e servi&#231;os   seguros, eficazes, acess&#237;veis e de boa qualidade &#233; fundamental para a   realiza&#231;&#227;o dos direitos de todas as pessoas usufruirem dos mais elevados n&#237;veis   de sa&#250;de f&#237;sica e mental.&#8221;<sup>2</sup></p>     <p>A ades&#227;o &#224;   TARV constitui o fator determinante do grau e dura&#231;&#227;o de supress&#227;o viral,<sup>3</sup> sendo v&#225;rios e complexos os fatores que influenciam esta condi&#231;&#227;o, que varia no   tempo. Um estudo realizado em Espanha demonstrou que ambientes sociofamiliares   inadequados diminuem a taxa de ader&#234;ncia &#224; TARV,<sup>4</sup> outro no Uganda   concluiu que, &#8220;em pacientes em TARV, a monitoriza&#231;&#227;o laboratorial de rotina   est&#225; associada a melhor sa&#250;de e sobrevida em compara&#231;&#227;o com o acompanhamento   cl&#237;nico apenas&#8221;.<sup>5</sup></p>     <p>Mo&#231;ambique   tem sofrido um impacto negativo da infe&#231;&#227;o pelo VIH resultante das altas taxas   de morbilidade e mortalidade. Um dos desafios &#233; a carga crescente sobre o   sistema de sa&#250;de, que sofria j&#225; de uma car&#234;ncia generalizada de profissionais,   sobretudo em &#225;reas rurais.</p>     <p>Em 2011,   Mo&#231;ambique tinha uma preval&#234;ncia estimada de VIH de 11,5%, dos quais 46%   estavam em TARV,<sup>6</sup> um aumento muito significativo comparativamente   aos 3.500 pacientes em tratamento em 2003, atestando o esfor&#231;o do Minist&#233;rio da   Sa&#250;de para levar a TARV a todos os distritos do pa&#237;s.</p>     <p>A   descentraliza&#231;&#227;o dos cuidados de VIH/SIDA dos hospitais de dia para os cuidados   de sa&#250;de prim&#225;rios (CSP), nos centros de sa&#250;de (CS) dos distritos, foi   precedida da forma&#231;&#227;o dos m&#233;dicos, t&#233;cnicos de medicina curativa, enfermeiros,   t&#233;cnicos de farm&#225;cia e agentes de medicina preventiva, atores principais dos   CSP no Servi&#231;o Nacional de Sa&#250;de (SNS) mo&#231;ambicano. Posteriormente foram   colocados nos CSP t&#233;cnicos de psicologia destinados ao aconselhamento dos   pacientes e nutricionistas predominantemente dedicados ao problema da   malnutri&#231;&#227;o infantil.</p>     <p>A nossa   experi&#234;ncia profissional durante seis anos nos servi&#231;os VIH dos CS das   prov&#237;ncias da Zamb&#233;zia e Nampula e testemunhos de outros profissionais de sa&#250;de   indicam que a inseguran&#231;a alimentar e a baixa acessibilidade aos CSP foram duas   das principais dificuldades na expans&#227;o da TARV em Mo&#231;ambique. </p>     <p>Nos &#250;ltimos   tr&#234;s anos, o n&#250;mero de abandonos da terapia tem aumentado significativamente,   colocando um novo desafio &#224; sa&#250;de p&#250;blica devido &#224; perigosidade do   desenvolvimento de resist&#234;ncia aos ARV quando a terapia &#233; interrompida.</p>     <p>Na prov&#237;ncia   de Nampula, a taxa de preval&#234;ncia da infe&#231;&#227;o por VIH encontrava-se abaixo dos   10% em 2007 (m&#233;dia nacional 16%).<sup>7</sup> Mas a baixa ades&#227;o &#224; TARV pode   provocar a dissemina&#231;&#227;o de v&#237;rus resistentes e o aumento da mortalidade. Nos 21   distritos desta prov&#237;ncia (com uma popula&#231;&#227;o de 4.887.839 habitantes em   fevereiro de 2014) estavam registados 106.197 pacientes VIH positivos, dos   quais 46% em TARV com 4,8% de abandonos. A incid&#234;ncia m&#233;dia da infe&#231;&#227;o pelo VIH   era de 4% nas gr&#225;vidas e de 2% no Aconselhamento e Testagem em Sa&#250;de (ATS).</p>     <p>Assim, o problema   do VIH continua preocupante e n&#227;o existe um conhecimento sistematizado sobre os   fatores determinantes de ades&#227;o terap&#234;utica nesta popula&#231;&#227;o em Nampula.<sup>8-10</sup></p>     ]]></body>
<body><![CDATA[<p>Confrontada   com esta situa&#231;&#227;o, a Faculdade de Ci&#234;ncias de Sa&#250;de (FCS) da Universidade L&#250;rio   prop&#244;s-se realizar um trabalho de investiga&#231;&#227;o operacional, destinado a avaliar   a ades&#227;o &#224; TARV na prov&#237;ncia de Nampula e propor e implementar atividades de   promo&#231;&#227;o da ades&#227;o terap&#234;utica. Este artigo apresenta o estudo da linha de base   inicial e tem tr&#234;s objetivos:</p>     <p>1) Avaliar a   ades&#227;o &#224; TARV,<sup>11-12</sup> nos CSP na prov&#237;ncia de Nampula;</p>     <p>2)   Identificar os fatores associados ao abandono da TARV na perce&#231;&#227;o dos   pacientes;</p>     <p>3)   Identificar os fatores associados ao abandono da TARV na perce&#231;&#227;o dos   profissionais de sa&#250;de.</p>     <p><b>M&#233;todos</b></p>     <p>Estudo   descritivo transversal, utilizando consulta documental das estat&#237;sticas da   Dire&#231;&#227;o Provincial de Sa&#250;de de Nampula (DPSN) e dos CS, utilizando m&#233;todos   quantitativos (inqu&#233;rito aos pacientes) e qualitativos (entrevistas aos   profissionais e sa&#250;de).<sup>13</sup></p>     <p>Universo:   Oito mil, duzentos e cinquenta e um pacientes inscritos em TARV nos CSP, em   terapia ou que abandonaram, em cinco CS das sedes dos distritos, durante o ano   de 2014. Respetivos profissionais dos CSP, respons&#225;veis pelos servi&#231;os TARV.</p>     <p>Amostra: O   n&#250;mero de pacientes que abandonaram a TARV a entrevistar em cada distrito foi   calculado utilizando a f&#243;rmula de Schuatz (n=&#949;2*p(1-p/i2), em que (<i>n</i>=n&#250;mero de sujeitos da amostra,   &#949;=1,962, <i>p</i>=&#250;ltima preval&#234;ncia da   taxa de abandono da TARV no CS, que era em m&#233;dia nos cinco CS de 12%,   considerando um intervalo de confian&#231;a=95%, com margem de erro de 5% <i>i</i>=0,05 margem de erro). Adicionaram-se   10% para perdas ocasionais ou desist&#234;ncias. O tamanho da amostra de pacientes   que abandonaram a TARV foi aplicado para os pacientes em tratamento, de modo a   permitir uma compara&#231;&#227;o das vari&#225;veis, totalizando 330 pacientes (165 pacientes   em TARV e 165 abandonos). Os sujeitos foram escolhidos aleatoriamente, segundo   uma data ao acaso de consulta ao servi&#231;o TARV (pacientes em terapia).   Utilizamos a amostragem &#171;bola de neve&#187; para encontrar os pacientes que, no   mesmo dia, tinham faltado &#224; consulta ou levantamento de ARV na farm&#225;cia do CS   h&#225; mais de dois meses (abandonaram a terapia), seguida de busca ativa (BA) e   manifesta&#231;&#227;o de disponibilidade individual (mediante explica&#231;&#227;o e assinatura de   termo de consentimento informado). Os profissionais de sa&#250;de foram selecionados   mediante disponibilidade individual e voluntariedade e, seguidamente,   entrevistados.</p>     <p>Crit&#233;rios de   inclus&#227;o: 1) distritos: distritos com preval&#234;ncia de VIH e taxa de abandono da   TARV superiores &#224; m&#233;dia provincial, geograficamente classificados nas   categorias utilizadas no Programa Nacional de Combate ao VIH/SIDA (cidade,   rural, corredor, litoral); 2) pacientes: inscritos em TARV com processo cl&#237;nico   localizado, maiores de idade, voluntariedade documentada em termo de   consentimento informado, explicado e assinado; 3) profissionais de sa&#250;de dos   CSP: atividade principal no servi&#231;o TARV, disponibilidade e voluntariedade.</p>     <p>Crit&#233;rios de   n&#227;o inclus&#227;o: paciente ou profissional que n&#227;o assina termo de consentimento   informado.</p>     ]]></body>
<body><![CDATA[<p>Vari&#225;veis   relativas aos distritos: n&#250;mero de pessoas VIH+ em seguimento, n&#250;mero de   pacientes em TARV, n&#250;mero de pacientes que abandonaram a TARV, incid&#234;ncia de   VIH. Vari&#225;veis relativas aos pacientes: distrito de resid&#234;ncia, g&#233;nero, idade,   em TARV, abandono, escolaridade, tempo em tratamento, n&#250;mero de tomas e de   comprimidos por dia, depress&#227;o, consumo de psicotr&#243;picos, apoio familiar,   perten&#231;a a Grupo de Apoio a Ades&#227;o Comunit&#225;rio (GAAC), utiliza&#231;&#227;o da medicina   tradicional, conhecimento sobre os riscos da m&#225; ades&#227;o, levantamento regular de   ARV na farm&#225;cia nos &#250;ltimos tr&#234;s meses, disponibilidade de alimentos, &#237;ndice de   massa corporal (IMC), alimenta&#231;&#227;o nas &#250;ltimas 24 horas, falha da medica&#231;&#227;o nas   &#250;ltimas 72 horas e no &#250;ltimo m&#234;s,<sup>14</sup> &#250;ltimo valor de contagem de   Linf&#243;citos T CD4 (CD4) e data, causas alegadas de abandono, ocorr&#234;ncia de   diarreia ou v&#243;mitos na &#250;ltima semana e de tuberculose (TB) no &#250;ltimo m&#234;s (<a href="#q1">Quadro I</a>).</p>     <p>&nbsp;</p>    <p align="center"><a name="q1"></a><img src="/img/revistas/rpmgf/v33n1/33n1a04q1.jpg"/></p>    
<p>&nbsp;</p>     <p>Vari&#225;veis   relativas aos profissionais dos CSP: a entrevista avaliou a sua opini&#227;o sobre   os pontos negativos na organiza&#231;&#227;o do servi&#231;o TARV, fatores percebidos   determinantes de abandono do TARV, n&#250;mero de GAACs funcionais, sinergias poss&#237;veis com a comunidade para melhorar a ades&#227;o terap&#234;utica (<a href="#q2">Quadro II</a>).</p>     <p>&nbsp;</p>    <p align="center"><a name="q2"></a><img src="/img/revistas/rpmgf/v33n1/33n1a04q2.jpg"/></p>    
<p>&nbsp;</p>      <p>Foram   analisados os dados de abandono da TARV atrav&#233;s dos registos da DPSN e dos CS   dos distritos e entrevistados os respons&#225;veis do programa TARV.</p>     <p>Foram   selecionados e treinados sete inquiridores (ensino secund&#225;rio completado,   flu&#234;ncia na l&#237;ngua local, sem liga&#231;&#227;o com o SNS, desconhecidos dos inquiridos),   assinado termo de compromisso &#233;tico para procederem &#224;s BA (dos pacientes que   tinham abandonado a TARV) num raio pedestre do CS (5km), sendo pagos 100   meticais (dois euros) por cada inqu&#233;rito realizado, acompanhado por um dos   investigadores.</p>     ]]></body>
<body><![CDATA[<p>O estudo   decorreu em quatro fases: 1) sele&#231;&#227;o dos distritos e CS (de fevereiro a agosto   de 2014), a partir da consulta documental dos registos da DPSN, crit&#233;rios   geogr&#225;ficos: CS 25 Setembro, Cidade Nampula - urbano; CS Nacaroa -   corredor; CS Lalaua - rural; CS Murrupula - corredor; CS Mossuril   - litoral; 2) identifica&#231;&#227;o dos grupos alvo, a partir dos registos dos CS   (em setembro de 2014): pacientes em TARV, pacientes que abandonaram a TARV;   consulta documental (estat&#237;sticas do CS e processos cl&#237;nicos); 3) recolha de   dados no terreno (entre outubro e novembro de 2014): aplica&#231;&#227;o de inqu&#233;ritos   aos pacientes,<sup>15-17</sup> avalia&#231;&#227;o dos registos no processo cl&#237;nico e de   levantamento de ARV nas farm&#225;cias; entrevistas aos profissionais de sa&#250;de   respons&#225;veis do programa TARV nos CSP; 4) tratamento da informa&#231;&#227;o (de dezembro   de 2014 a fevereiro de 2015): introdu&#231;&#227;o de dados em programa <i>Statistical Package for Social Sciences, vs.</i> 21, tratamento e an&#225;lise de dados invari&#225;vel e interpreta&#231;&#227;o dos resultados.</p>     <p>O protocolo   do estudo foi aprovado pelo Comit&#233; Institucional de Bio&#233;tica para a Sa&#250;de da   Universidade L&#250;rio e pela DPSN e o estudo respeitou todas as recomenda&#231;&#245;es da   Declara&#231;&#227;o de Hels&#237;nquia (2013).</p>     <p><b>Resultados</b></p>     <p>Nos cinco   distritos estudados (com uma popula&#231;&#227;o de 246.683 habitantes em outubro de   2014), os dados estat&#237;sticos mostram 19.834 pacientes VIH positivos, dos quais   42% em TARV com uma m&#233;dia de 11% de abandono (variando de 40% em Nacaroa at&#233; 7%   em Nampula), ultrapassando em todos os casos os n&#250;meros apresentados pela DPSN.   A incid&#234;ncia m&#233;dia da infe&#231;&#227;o pelo VIH no mesmo m&#234;s de outubro era de 7% nas   gr&#225;vidas e de 10% no ATS.</p>     <p>Da amostra   inicialmente calculada de 330 pacientes foram inquiridos 295 sujeitos nos cinco   CS (<a href="#q3">Quadro III</a>), 208 em TARV, ultrapassando o valor calculado de amostra (165)   para compensar a perca de abandonos, em n&#250;mero de 86, inferior ao previsto   devido a informa&#231;&#227;o inexistente ou incorreta nos processos cl&#237;nicos para a sua   localiza&#231;&#227;o pelos inquiridores nas BA, e ainda um paciente que n&#227;o tinha   iniciado a TARV. De uma lista de 235 abandonos foram selecionados 165 pacientes   com informa&#231;&#227;o registada suficiente para a busca; destes, 32% tinham morada ou   nome falso, 17% tinham mudado de resid&#234;ncia, 8% eram &#243;bitos; dos 73 (43%) de   abandonos encontrados, 60 (82%) responderam ao inqu&#233;rito e foram referidos ao   CS; estes mesmos pacientes convidaram outros 26 abandonos que n&#227;o estavam na   lista de buscas, mas que responderam ao inqu&#233;rito e foram referidos ao CS. As   caracter&#237;sticas demogr&#225;ficas (g&#233;nero, idade, resid&#234;ncia) e sociais (grupo   &#233;tnico-lingu&#237;stico, escolaridade, fonte de renda, atividade econ&#243;mica, dieta,   cren&#231;as tradicionais) s&#227;o id&#234;nticas para o grupo em TARV e para o grupo que abandonou em cada CS.</p>     <p>&nbsp;</p>    <p align="center"><a name="q3"></a><img src="/img/revistas/rpmgf/v33n1/33n1a04q3.jpg"/></p>    
<p>&nbsp;</p>      <p>Dos 295   sujeitos inquiridos o g&#233;nero feminino representa 70% do grupo, com idades entre   os 18 e os 62 anos. Verificamos que o abandono se manifesta inversamente   proporcional &#224; idade (<a href="#q4">Quadro IV</a>) e que 81% tem um n&#237;vel de escolaridade   insuficiente (analfabetos ou n&#237;vel prim&#225;rio) para o dom&#237;nio da l&#237;ngua portuguesa oficial do pa&#237;s (compreens&#227;o e express&#227;o limitadas). </p>     <p>&nbsp;</p>    ]]></body>
<body><![CDATA[<p align="center"><a name="q4"></a><img src="/img/revistas/rpmgf/v33n1/33n1a04q4.jpg"/></p>    
<p>&nbsp;</p>      <p>O principal   motivo evocado pelos 86 pacientes que abandonaram a TARV &#233; o estigma ligado &#224;   infe&#231;&#227;o pelo VIH, seguido pela mudan&#231;a tempor&#225;ria de resid&#234;ncia e pelos efeitos secund&#225;rios dos ARV. O <a href="#q5">Quadro V</a> mostra as causas referidas por estes pacientes.</p>     <p>&nbsp;</p>    <p align="center"><a name="q5"></a><img src="/img/revistas/rpmgf/v33n1/33n1a04q5.jpg"/></p>    
<p>&nbsp;</p>      <p>Os sinais ou   sintomas de depress&#227;o est&#227;o, ou estiveram presentes, em 37% do grupo (295), mas   a maioria (82%) declara que n&#227;o consome psicotr&#243;picos (o consumo de &#225;lcool &#233;   referido por 15%); a inseguran&#231;a alimentar &#233; mencionada por 58% do grupo e   confirmada pelo question&#225;rio de frequ&#234;ncia alimentar nas &#250;ltimas 24 horas: 56%   n&#227;o consumiram fruta, 47% n&#227;o comeram prote&#237;na animal, 32% n&#227;o comeram prote&#237;na   vegetal, 26% n&#227;o comeram qualquer prote&#237;na, 22% n&#227;o consumiram legumes, 21%   tiveram uma &#250;nica refei&#231;&#227;o no dia anterior; a magreza (IMC &lt;18,5) ocorre em   12%.</p>     <p>V&#225;rios   fatores associados ao abandono da TARV t&#234;m uma preval&#234;ncia superior   estatisticamente significativa no grupo que abandonou: in&#237;cio mais recente do   tratamento, maior n&#250;mero de tomas di&#225;rias de ARV, falta de apoio familiar, desconhecimento dos GAACs e dos riscos da m&#225; ades&#227;o terap&#234;utica (<a href="#q6">Quadro VI</a>).</p>     <p>&nbsp;</p>    <p align="center"><a name="q6"></a><img src="/img/revistas/rpmgf/v33n1/33n1a04q6.jpg"/></p>    
]]></body>
<body><![CDATA[<p>&nbsp;</p>      <p>Nos   pacientes em tratamento (208) 27% falharam pelo menos uma toma nos &#250;ltimos tr&#234;s   dias e 33% falharam pelo menos uma vez no &#250;ltimo m&#234;s (a falha de duas ou mais   tomas foi constatada em 23%); 26% n&#227;o levantaram regularmente os ARV na   farm&#225;cia do CS nos &#250;ltimos tr&#234;s meses (o levantamento de medicamentos para   todos estes pacientes est&#225; limitado &#224; farm&#225;cia do CS). A boa ades&#227;o dos   pacientes &#224; TARV (&gt;95% das tomas), m&#233;dia estimada nos cinco distritos para   os &#250;ltimos tr&#234;s meses, situa-se nos 69%, mas 36% apresentam um resultado mau ou   med&#237;ocre na contagem de CD4 (&lt;350) e 63% n&#227;o est&#227;o a cumprir o protocolo de   acompanhamento da TARV recomendado pelo Minist&#233;rio da Sa&#250;de (contagem semestral   de CD4). A ocorr&#234;ncia de diarreia ou v&#243;mitos na &#250;ltima semana &#233; referida por   18% e a incid&#234;ncia de tuberculose no &#250;ltimo m&#234;s &#233; referida por 9%.</p>     <p>Os 31   profissionais dos CSP respons&#225;veis dos servi&#231;os TARV entrevistados (cinco   m&#233;dicos, cinco t&#233;cnicos de medicina, cinco enfermeiras de sa&#250;de   materno-infantil, dois t&#233;cnicos de psicologia, dois enfermeiros do Programa de   Combate &#224; Tuberculose, um licenciado e quatro t&#233;cnicos de farm&#225;cia, tr&#234;s   rececionistas, um nutricionista) transmitiram uma opini&#227;o da subestimada taxa   de abandono da TARV, que a estigmatiza&#231;&#227;o da doen&#231;a e as dificuldades   alimentares constituem os fatores percebidos como determinantes principais da   m&#225; ades&#227;o e do abandono, apontando ainda o deficiente registo cl&#237;nico como um dos principais obst&#225;culos ao acompanhamento eficiente destes pacientes (<a href="#q7">Quadro VII</a>).</p>     <p>&nbsp;</p>    <p align="center"><a name="q7"></a><img src="/img/revistas/rpmgf/v33n1/33n1a04q7.jpg"/></p>    
<p>&nbsp;</p>      <p><b>Discuss&#227;o</b></p>     <p>Os   investigadores confrontaram-se inicialmente com informa&#231;&#227;o insuficiente e pouco   fi&#225;vel a n&#237;vel central na DPSN e nos CS, incluindo a constante nos processos   cl&#237;nicos que n&#227;o permite a busca ativa de faltosos e abandonos. As taxas de   abandono da TARV est&#227;o subestimadas nas estat&#237;sticas da DPSN e na maioria dos   CS.</p>     <p>Os   principais motivos apontados para o abandono da TARV s&#227;o o estigma e a   discrimina&#231;&#227;o, j&#225; apontados por outros autores.<sup>18</sup> A aus&#234;ncia de   apoio familiar &#233; referida por mais de metade do grupo e significativamente mais   prevalente nos que abandonaram a TARV.<sup>19</sup> O baixo n&#237;vel de escolaridade,   poder&#225; explicar a segunda causa referida de abandono, a viagem, na medida em   que os pacientes mudavam de resid&#234;ncia mas n&#227;o faziam a transfer&#234;ncia de   documenta&#231;&#227;o provis&#243;ria para beneficiar da TARV no novo CS.<sup>20</sup></p>     <p>A suspeita   de diagn&#243;stico de depress&#227;o &#233; bastante prevalente e confirma outros estudos,<sup>21-22</sup> n&#227;o constando, no entanto, em nenhum registo cl&#237;nico; tamb&#233;m a maioria dos CS   n&#227;o disp&#245;e de psicotr&#243;picos antidepressivos, demonstrando a defici&#234;ncia dos CSP   no que respeita &#224; sa&#250;de mental.<sup>23-26</sup></p>     ]]></body>
<body><![CDATA[<p>A inseguran&#231;a   alimentar &#233; de alta preval&#234;ncia neste grupo,<sup>27</sup> n&#227;o sendo, no   entanto, referida pelos pacientes como causa direta de abandono.</p>     <p>Embora o mau   atendimento no CS ocupe o &#250;ltimo lugar nas causas de abandono, pelo n&#250;mero de   tomas e de comprimidos (superiores ao estipulado no programa TARV),<sup>28-30</sup> pela data da &#250;ltima colheita de CD4 (superior a seis meses) e pela falta de   conhecimento dos pacientes sobre os riscos de m&#225; ades&#227;o, poder-se-&#225; inferir que   muitos pacientes n&#227;o est&#227;o a cumprir o protocolo recomendado para a TARV devido   a um atendimento deficit&#225;rio nos CSP.</p>     <p>Ainda o   papel dos GAACs no apoio a estes pacientes, na sua perspetiva, apresenta-se   insignificante em todos os distritos e mesmo discut&#237;vel a sua utilidade.</p>     <p>Nos   pacientes em TARV, a boa ades&#227;o (&gt;95% das tomas) m&#233;dia estimada nos cinco   distritos para os &#250;ltimos tr&#234;s meses (69%) est&#225; abaixo da m&#233;dia regional e de   outros estudos em &#193;frica,<sup>31</sup> o que pode explicar os resultados   insuficientes na contagem de CD4 (&lt;350) e a ocorr&#234;ncia de infe&#231;&#245;es oportunistas   (27%), aumentando o risco de estirpes de VIH resistentes.</p>     <p>O abandono   da TARV em Nampula &#233; um problema grave e complexo resultante de fatores   individuais (baixo n&#237;vel escolar e econ&#243;mico),<sup>32</sup> sociais (estigma,   discrimina&#231;&#227;o, falta de apoio familiar) e do funcionamento deficiente dos CSP.</p>     <p>Foram   considerados os seguintes vieses para a realiza&#231;&#227;o deste estudo e respetivos   modos de preven&#231;&#227;o: vieses institucionais - fiabilidade baixa dos   registos estat&#237;sticos de indicadores de sa&#250;de, controlada pela recolha <i>in loco</i> nos CS; insufici&#234;ncias nos   registos cl&#237;nicos individuais, controladas pelo exame cl&#237;nico dos pacientes;   vieses do grupo alvo - fiabilidade das respostas aos inqu&#233;ritos,   controlada por triangula&#231;&#227;o de perguntas, dos registos nos processos cl&#237;nicos e   na farm&#225;cia do CS, para evitar vieses de aferi&#231;&#227;o e de conclus&#227;o. O processo de   sele&#231;&#227;o e o n&#250;mero da amostra dos dois grupos (em TARV e abandonos) foi   diferente; no entanto, as caracter&#237;sticas dos sujeitos s&#227;o id&#234;nticas e o   processo de recolha de dados foi igual. A predomin&#226;ncia do g&#233;nero feminino nos   dois grupos, ligeiramente inferior no grupo de abandonos, traduz a melhor   ades&#227;o deste aos cuidados de sa&#250;de. Assim, consideramos que a amostra recolhida   em cinco distritos de caracter&#237;sticas geogr&#225;ficas distintas, englobando todas   as faixas et&#225;rias da popula&#231;&#227;o adulta de ambos os g&#233;neros e de caracter&#237;sticas   sociais e econ&#243;micas muito semelhantes, &#233; representativa da popula&#231;&#227;o em TARV   na prov&#237;ncia de Nampula.</p>     <p>Como   implica&#231;&#245;es pr&#225;ticas considera-se necess&#225;rio melhorar o sistema de registo e   arquivo cl&#237;nico dos pacientes em TARV, assim como o sistema de informa&#231;&#227;o da   sa&#250;de.<sup>33-34</sup> Por outro lado, a literatura aconselha a desenvolver uma   a&#231;&#227;o interdisciplinar junto de pacientes e fam&#237;lias (informa&#231;&#227;o e educa&#231;&#227;o para   a sa&#250;de, organiza&#231;&#227;o e forma&#231;&#227;o dos GAACs, extens&#227;o rural com vista &#224; produ&#231;&#227;o   local de prote&#237;na vegetal, legumes e frutas por parte das fam&#237;lias), dos   profissionais de sa&#250;de (organiza&#231;&#227;o e referencia&#231;&#227;o aos GAACs, visitas   domicili&#225;rias, forma&#231;&#227;o em estrat&#233;gias de preven&#231;&#227;o da m&#225; ades&#227;o)<sup>35-37</sup> e dos praticantes tradicionais de sa&#250;de (PTS) (alimenta&#231;&#227;o saud&#225;vel, doen&#231;as   cr&#243;nicas, dinamiza&#231;&#227;o dos GAACs), de forma recorrente e acompanhada para   conseguir inverter esta situa&#231;&#227;o e diminuir a morbilidade e mortalidade   provocadas pelo VIH, assim como a sua incid&#234;ncia. </p>     <p>&nbsp;</p>     <p><b>REFER&#202;NCIAS   BIBLIOGR&#193;FICAS</b></p>     <!-- ref --><p>1. UNAIDS.   UNAIDS report on the global AIDS epidemic 2010 (Internet). UNAIDS; 2010. ISBN 9789291738717. Available from: <a href="http://www.unaids.org/globalreport" target="_blank">http://www.unaids.org/globalreport</a> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366306&pid=S2182-5173201700010000400001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>2. United   Nations. Political declaration on HIV/AIDS: intensifying our efforts to   eliminate HIV/AIDS: draft resolution submitted by the President of the General   Assembly (A/65/L.77) (Internet). United Nations; 2011. Available from: <a href="http://www.un.org/ga/search/view_doc.asp?symbol=A/65/L.77" target="_blank">http://www.un.org/ga/search/view_doc.asp?symbol=A/65/L.77</a> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366307&pid=S2182-5173201700010000400002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>3. Jesus E.   Clinical significance of simplicity and adherence in antiretroviral therapy.   Clinical Care Options.com (Internet); 2007. Available from: <a href="https://www.clinicaloptions.com/HIV/Treatment%20Updates/Simple/Modules/Module%202.aspx" target="_blank">https://www.clinicaloptions.com/HIV/Treatment%20Updates/Simple/Modules/Module%202.aspx</a> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366308&pid=S2182-5173201700010000400003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>4. Arrondo   Velasco A, Sainz Suberviola ML, Andr&#233;s Esteban EM, Iruin Sanz AI, Napal   Lecumberri V. Factores relacionados con la adherencia en pacientes infectados   por el virus de la inmunodeficiencia humana (Factors associated with adherence   in HIV patients). Farm Hosp. 2009;33(1):4-11. Spanish</p>     <!-- ref --><p>5. Mermin J,   Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine   viral load, CD4 cell count, and clinical monitoring among adults with HIV   receiving antiretroviral therapy in Uganda: randomised trial. BMJ.   2011;343:d6792.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366310&pid=S2182-5173201700010000400005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>6. African   Health Observatory. Atlas of African health statistics 2014: health situation   analysis of the African Region (Internet). Brazzaville: World Health   Organization, Regional Office for Africa; 2014. ISBN 9789290232254. Available from: <a href="http://www.aho.afro.who.int/sites/default/files/publications/921/AFRO-Statistical_Factsheet.pdf" target="_blank">http://www.aho.afro.who.int/sites/default/files/publications/921/AFRO-Statistical_Factsheet.pdf</a> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366312&pid=S2182-5173201700010000400006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>7. Grupo   T&#233;cnico Multisectorial de Apoio &#224; Luta contra o HIV/SIDA em Mo&#231;ambique. Ronda   de vigil&#226;ncia epidemiol&#243;gica do HIV de 2007 (Internet). Maputo: Direc&#231;&#227;o Nacional da Assist&#234;ncia M&#233;dica; 2008. Available from: <a href="http://www.rosc.org.mz/index.php/documentos/doc_details/67-ronda-de-vigilancia-epidemiologica-do-hiv-de-2007" target="_blank">http://www.rosc.org.mz/index.php/documentos/doc_details/67-ronda-de-vigilancia-epidemiologica-do-hiv-de-2007</a> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366313&pid=S2182-5173201700010000400007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>8. Nachega   JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in   care in middle-income and low-income countries: current status of knowledge and   research priorities. Curr Opin HIV AIDS. 2010;5(1):70-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366314&pid=S2182-5173201700010000400008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>9. Reynolds   NR. Adherence to antiretroviral therapies: state of the science. Curr HIV Res.   2004;2(3):207-14.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366316&pid=S2182-5173201700010000400009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>10.   Marcellin F, Spire B, Carrieri MP, Roux P. Assessing adherence to   antiretroviral therapy in randomized HIV clinical trials: a review of currently   used methods. Expert Rev Anti Infect Ther. 2013;11(3):239-50.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366318&pid=S2182-5173201700010000400010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>11. Williams   AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring   medication adherence in research. AIDS Behav. 2013;17(1):284-97.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366320&pid=S2182-5173201700010000400011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>12. Berg KM,   Arnsten JH. Practical and conceptual challenges in measuring antiretroviral   adherence. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S79-87.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366322&pid=S2182-5173201700010000400012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>13. Sankar   A, Golin C, Simoni JM, Luborsky M, Pearson C. How qualitative methods   contribute to understanding combination antiretroviral therapy adherence. J   Acquir Immune Defic Syndr. 2006;43 Suppl 1:S54-68.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366324&pid=S2182-5173201700010000400013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>14. Sullivan   PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, Jakashima AK. Patient and   regimen characteristics associated with self-reported non adherence to   antiretroviral therapy. PLoS One. 2007;2(6):e552.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366326&pid=S2182-5173201700010000400014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>15. Stubbs   BA, Micek MA, Pfeiffer JT, Montoya P, Gloyd S. Treatment partners and adherence   to HAART in Central Mozambique. AIDS Care. 2009; 21(11):1412-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366328&pid=S2182-5173201700010000400015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>16. Bulgiba   A, Mohammed UY, Chik Z, Lee C, Peramalah D. How well does self-reported   adherence fare compared to therapeutic drug monitoring in HAART? Prev Med.   2013;57 Suppl:S34-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366330&pid=S2182-5173201700010000400016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>17.   Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact   of specific HIV treatment-related adverse events on adherence to antiretroviral   therapy: a systematic review and meta-analysis. AIDS Care. 2013;25(4):400-14.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366332&pid=S2182-5173201700010000400017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>18. Peltzer   K, Pengpid S. Socioeconomic factors in adherence to HIV therapy in low- and   middle-income countries. J Health Popul Nutr. 2013;31(2):150-70.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366334&pid=S2182-5173201700010000400018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>19. Simoni   JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report   measures of antiretroviral therapy adherence: a review with recommendations for   HIV research and clinical management. AIDS Behav. 2006;10(3):227-45.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366336&pid=S2182-5173201700010000400019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>20. Falagas   ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a   determinant of adherence to treatment in HIV infected patients: a systematic   review of the literature. Retrovirology. 2008;5:13.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366338&pid=S2182-5173201700010000400020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>21.   Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, et al.   Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan   Africa: a systematic review. AIDS Behav. 2012;16(8):2101-18.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366340&pid=S2182-5173201700010000400021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>22. Lucas   GM. Substance abuse, adherence with antiretroviral therapy, and clinical   outcomes among HIV-infected individuals. Life Sci. 2011;88(21-22):948-52.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366342&pid=S2182-5173201700010000400022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>23. Nel A,   Kagee A. Common mental health problems and antiretroviral therapy adherence.   AIDS Care. 2011;23(11):1360-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366344&pid=S2182-5173201700010000400023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>24. Nancy R.   Optimizing adherence to antiretroviral therapy. In: Eron Jr JJ, Kuritzkes DR,   Squires KE, editors. inPractice.com (Internet); 2014 (cited 2014 May 24;   updated 2016 Apr 1). Available from: <a href="https://www.inpractice.com/Textbooks/HIV/Antiretroviral_Therapy/ch13_pt1_Adherence" target="_blank">https://www.inpractice.com/Textbooks/HIV/Antiretroviral_Therapy/ch13_pt1_Adherence</a>  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366346&pid=S2182-5173201700010000400024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>25.   Sandelowski M, Voils CI, Chang Y, Lee EJ. A systematic review comparing   antiretroviral adherence descriptive and intervention studies conducted in the   USA. AIDS Care. 2009;21(8):953-66.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366347&pid=S2182-5173201700010000400025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>26. Conway   B. The role of adherence to antiretroviral therapy in the management of HIV   infection. J Acquir Immune Defic Syndr. 2007;45 Suppl 1:S14-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366349&pid=S2182-5173201700010000400026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>27.   Emamzadeh-Fard S, Fard SE, SeyedAlinaghi S, Paydary K. Adherence to   anti-retroviral therapy and its determinants in HIV/AIDS patients: a review.   Infect Disord Drug Targets. 2012;12(5):346-56.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366351&pid=S2182-5173201700010000400027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>28. Nischal   KC, Khopkar U, Saple DG. Improving adherence to antiretroviral therapy. Indian   J Dermatol Venereol Leprol. 2005;71(5):316-20.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366353&pid=S2182-5173201700010000400028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>29. Reisner   SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV   antiretroviral adherence and intervention studies among HIV-infected youth. Top   HIV Med. 2009;17(1):14-25.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366355&pid=S2182-5173201700010000400029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>30. Redfield   RR, Blattner WA. New directions in HIV therapy and prevention: the next 25   years. In: Sanders S, editor. From cause to care: commemorating 25 years of   HIV/AIDS research (Internet).&nbsp; Baltimore: The American Association for the Advancement of Science;   2009. p. 35-7. Available from: <a href="http://www.sciencemag.org/site/products/collectionbooks/HIV25.pdf" target="_blank">http://www.sciencemag.org/site/products/collectionbooks/HIV25.pdf</a>   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366357&pid=S2182-5173201700010000400030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>31. Mills   EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to   antiretroviral therapy in sub-Saharan Africa and North America: a   meta-analysis. JAMA. 2006;296(6):679-90.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366358&pid=S2182-5173201700010000400031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>32. Rachlis   BS, Mills EJ, Cole DC. Livelihood security and adherence to antiretroviral   therapy in low and middle income settings: a systematic review. PLoS One. 2011;6(5):e18948.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366360&pid=S2182-5173201700010000400032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>33. Simoni   JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions:   translating research findings to the real world clinic. Curr HIV/AIDS Rep.   2010;7(1):44-51.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366362&pid=S2182-5173201700010000400033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>     <!-- ref --><p>34. Leeman   J, Chang YK, Lee EJ, Voils CI, Crandell J, Sandelowski M. Implementation of   antiretroviral therapy adherence interventions: a realist synthesis of   evidence. J Adv Nurs. 2010;66(9):1915-30.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366364&pid=S2182-5173201700010000400034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>35.   Bangsberg DR. Preventing HIV antiretroviral resistance through better   monitoring of treatment adherence. J Infect Dis. 2008;197 Suppl 3:S272-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366366&pid=S2182-5173201700010000400035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>36.   Machtinger EL, Bangsberg DR. Seven steps to better adherence: a practical   approach to promoting adherence to antiretroviral therapy. AIDS Read.   2007;17(1):43-51.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366368&pid=S2182-5173201700010000400036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>37. Amico   KR, Orrell C. Antiretroviral therapy adherence support: recommendations and   future directions. J Int Assoc Provid AIDS Care. 2013;12(2):128-37.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1366370&pid=S2182-5173201700010000400037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <p>&nbsp;</p>     <p><a href="#topc0">Endere&ccedil;o para correspond&ecirc;ncia</a> | <a href="#topc0">Direcci&oacute;n para correspondencia</a> | <a href="#topc0">Correspondence</a><a name="c0"></a></p>      <p>Paulo Das   Neves Pires</p>     <p>Universidade   Lurio, Mo&#231;ambique</p>     <p>E-mail: <a href="mailto:druidatom@gmail.com">druidatom@gmail.com</a>   </p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><b>Agradecimentos</b></p>     <p>Armindo   Tonela (DPSN); N&#233;rsio Malumbe e Janu&#225;rio J&#250;nior (CS Lalaua); Ermenogildo   Mulenga, Ivan Alberto, Edinete Liacha e Saide Maquina (CS Mossuril); Aguinaldo   Mariano e Albino Maricoa (CS Murrupula); Eunice Zeca, Domingos Andrade, Gilda   Gra&#231;a e Esperan&#231;a Francisco (CS Nacaroa); Carlos Felicidade e An&#237;bal Muteca (CS   25 de Setembro, Nampula).</p>     <p><b>Conflitos de interesse</b></p>     <p>Os autores   declaram n&#227;o ter quaisquer conflitos de interesse.</p>     <p>&nbsp;</p>     <p><b>Recebido em 23-03-2016</b></p>     <p><b>Aceite para publica&#231;&#227;o em 23-01-2017</b></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>UNAIDS</collab>
<source><![CDATA[UNAIDS report on the global AIDS epidemic 2010]]></source>
<year>2010</year>
<publisher-name><![CDATA[UNAIDS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>United Nations</collab>
<source><![CDATA[Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS: draft resolution submitted by the President of the General Assembly (A/65/L.77)]]></source>
<year>2011</year>
<publisher-name><![CDATA[United Nations]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jesus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical significance of simplicity and adherence in antiretroviral therapy: Clinical Care Options.com]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrondo Velasco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sainz Suberviola]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés Esteban]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Iruin Sanz]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Napal Lecumberri]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Factores relacionados con la adherencia en pacientes infectados por el virus de la inmunodeficiencia humana]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2009</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-11</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mermin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ekwaru]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Were]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Degerman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bunnell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kaharuza]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2011</year>
<volume>343</volume>
<page-range>d6792</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>African Health Observatory</collab>
<source><![CDATA[Atlas of African health statistics 2014: health situation analysis of the African Region]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Brazzaville ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization, Regional Office for Africa]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Grupo Técnico Multisectorial de Apoio à Luta contra o HIV/SIDA em Moçambique</collab>
<source><![CDATA[Ronda de vigilância epidemiológica do HIV de 2007]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Maputo ]]></publisher-loc>
<publisher-name><![CDATA[Direcção Nacional da Assistência Médica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nachega]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schechter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities]]></article-title>
<source><![CDATA[Curr Opin HIV AIDS]]></source>
<year>2010</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>70-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adherence to antiretroviral therapies: state of the science]]></article-title>
<source><![CDATA[Curr HIV Res]]></source>
<year>2004</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>207-14</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcellin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Spire]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Carrieri]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Roux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods]]></article-title>
<source><![CDATA[Expert Rev Anti Infect Ther]]></source>
<year>2013</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>239-50</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Amico]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Bova]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Womack]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A proposal for quality standards for measuring medication adherence in research]]></article-title>
<source><![CDATA[AIDS Behav]]></source>
<year>2013</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>284-97</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Arnsten]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Practical and conceptual challenges in measuring antiretroviral adherence]]></article-title>
<source><![CDATA[J Acquir Immune Defic Syndr]]></source>
<year>2006</year>
<volume>43</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S79-87</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sankar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Golin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Simoni]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Luborsky]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[How qualitative methods contribute to understanding combination antiretroviral therapy adherence]]></article-title>
<source><![CDATA[J Acquir Immune Defic Syndr]]></source>
<year>2006</year>
<volume>43</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S54-68</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Campsmith]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Begley]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Schulden]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jakashima]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Patient and regimen characteristics associated with self-reported non adherence to antiretroviral therapy]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2007</year>
<volume>2</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>e552</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stubbs]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Micek]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeiffer]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gloyd]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment partners and adherence to HAART in Central Mozambique]]></article-title>
<source><![CDATA[AIDS Care]]></source>
<year>2009</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1412-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bulgiba]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammed]]></surname>
<given-names><![CDATA[UY]]></given-names>
</name>
<name>
<surname><![CDATA[Chik]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Peramalah]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[How well does self-reported adherence fare compared to therapeutic drug monitoring in HAART]]></article-title>
<source><![CDATA[Prev Med]]></source>
<year>2013</year>
<volume>57</volume>
<page-range>S34-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Dakkak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McCann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gadkari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Prajapati]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maiese]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[AIDS Care]]></source>
<year>2013</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>400-14</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peltzer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Pengpid]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Socioeconomic factors in adherence to HIV therapy in low- and middle-income countries]]></article-title>
<source><![CDATA[J Health Popul Nutr]]></source>
<year>2013</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>150-70</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simoni]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kurth]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Pantalone]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Merrill]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Frick]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management]]></article-title>
<source><![CDATA[AIDS Behav]]></source>
<year>2006</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>227-45</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falagas]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Zarkadoulia]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Pliatsika]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Panos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature]]></article-title>
<source><![CDATA[Retrovirology]]></source>
<year>2008</year>
<volume>5</volume>
<page-range>13</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakimuli-Mpungu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bass]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Alexandre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Musisi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ram]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review]]></article-title>
<source><![CDATA[AIDS Behav]]></source>
<year>2012</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2101-18</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals]]></article-title>
<source><![CDATA[Life Sci]]></source>
<year>2011</year>
<volume>88</volume>
<numero>21-22</numero>
<issue>21-22</issue>
<page-range>948-52</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kagee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Common mental health problems and antiretroviral therapy adherence]]></article-title>
<source><![CDATA[AIDS Care]]></source>
<year>2011</year>
<volume>23</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1360-5</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nancy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Optimizing adherence to antiretroviral therapy]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Eron Jr]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kuritzkes]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Squires]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<source><![CDATA[inPractice.com]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandelowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Voils]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA]]></article-title>
<source><![CDATA[AIDS Care]]></source>
<year>2009</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>953-66</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conway]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of adherence to antiretroviral therapy in the management of HIV infection]]></article-title>
<source><![CDATA[J Acquir Immune Defic Syndr]]></source>
<year>2007</year>
<volume>45</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S14-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emamzadeh-Fard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fard]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[SeyedAlinaghi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Paydary]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: a review]]></article-title>
<source><![CDATA[Infect Disord Drug Targets]]></source>
<year>2012</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>346-56</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nischal]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Khopkar]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Saple]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Improving adherence to antiretroviral therapy]]></article-title>
<source><![CDATA[Indian J Dermatol Venereol Leprol]]></source>
<year>2005</year>
<volume>71</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>316-20</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reisner]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Mimiaga]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Skeer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovich]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Safren]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth]]></article-title>
<source><![CDATA[Top HIV Med]]></source>
<year>2009</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-25</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Redfield]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Blattner]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[New directions in HIV therapy and prevention: the next 25 years]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[From cause to care: commemorating 25 years of HIV/AIDS research]]></source>
<year>2009</year>
<page-range>35-7</page-range><publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
<publisher-name><![CDATA[The American Association for the Advancement of Science]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nachega]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Buchan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Orbinski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Attaran]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2006</year>
<volume>296</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>679-90</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rachlis]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cole]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Livelihood security and adherence to antiretroviral therapy in low and middle income settings: a systematic review]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2011</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e18948</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simoni]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Amico]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antiretroviral adherence interventions: translating research findings to the real world clinic]]></article-title>
<source><![CDATA[Curr HIV/AIDS Rep]]></source>
<year>2010</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-51</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leeman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Voils]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Crandell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sandelowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Implementation of antiretroviral therapy adherence interventions: a realist synthesis of evidence]]></article-title>
<source><![CDATA[J Adv Nurs]]></source>
<year>2010</year>
<volume>66</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1915-30</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bangsberg]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Preventing HIV antiretroviral resistance through better monitoring of treatment adherence]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2008</year>
<volume>197</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S272-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machtinger]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Bangsberg]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Seven steps to better adherence: a practical approach to promoting adherence to antiretroviral therapy]]></article-title>
<source><![CDATA[AIDS Read]]></source>
<year>2007</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-51</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amico]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Orrell]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antiretroviral therapy adherence support: recommendations and future directions]]></article-title>
<source><![CDATA[J Int Assoc Provid AIDS Care]]></source>
<year>2013</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>128-37</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
